Home・Aktien・Krystal Biotech Inc

Krystal Biotech Inc

Geschlossen

BrancheGesundheitswesen

324.45 0.83

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

319.48

Max

326.37

Schlüsselkennzahlen
By Trading Economics
Einkommen	-1.2M 55M
Verkäufe	2.9M 119M
KGV Branchendurchschnitt	45.697 68.51
EPS	1.79
Gewinnspanne	45.938
Angestellte	295
EBITDA	2.9M 66M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+24.95% upside

Dividenden
By Acuity
Nächstes Ergebnis	2. Nov. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-1.1B 9.3B
Vorheriger Eröffnungskurs	323.62
Vorheriger Schlusskurs	324.45

Krystal Biotech Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

7. Aug. 2026, 19:26 UTC

Krystal Biotech Inc shares are higher during Friday's session, reflecting a gain since Thursday's close. No specific news was identified to explain the movement.

6. Aug. 2026, 19:26 UTC

Shares of Krystal Biotech Inc. are lower today, trading near the lower end of their one-month range and below the 20-day moving average.

5. Aug. 2026, 19:52 UTC

Krystal Biotech Inc shares are lower today, breaking a trend of higher closes. Broader market sentiment is cautious following ADP's weak employment report.

4. Aug. 2026, 20:04 UTC

News

Citigroup raised its price target on Krystal Biotech to $386, contributing to upward movement in shares despite earlier session pullbacks.

3. Aug. 2026, 23:06 UTC

Krystal Biotech Inc shares are higher in after-market hours, recovering from an earlier dip. Broader market sentiment improved following stronger-than-expected economic data.

31. Juli 2026, 23:06 UTC

Krystal Biotech Inc is trading lower in after-market hours amid volatility, with no specific news identified to explain the movement.

30. Juli 2026, 19:39 UTC

Krystal Biotech Inc shares are higher today, maintaining gains since Wednesday's close. The stock remains above its 20-day moving average despite a slight pullback.

29. Juli 2026, 20:04 UTC

Krystal Biotech shares are lower amid a broader market decline, influenced by significant drops in major U.S. stocks ahead of the Federal Reserve's announcement.

28. Juli 2026, 20:03 UTC

Event

Social Media

Krystal Biotech Inc. shares rise amid strong Biotechnology sector gains and positive social media discussions, with Q2 FY2026 earnings expected on August 3.

27. Juli 2026, 22:02 UTC

Social Media

Shares of Krystal Biotech are lower in after-market hours, despite discussions of potential catalysts and an upcoming earnings report on August 3.

24. Juli 2026, 19:11 UTC

Krystal Biotech Inc shares are higher today, despite broader market weakness. The stock has seen increased trading activity since Thursday's close.

23. Juli 2026, 10:01 UTC

Krystal Biotech Inc shares are higher in pre-market hours, following a slight after-market increase on Wednesday. No specific news was identified for this movement.

22. Juli 2026, 19:26 UTC

Krystal Biotech Inc shares are lower today amid a broader market decline, with no specific company news identified to explain the movement.

21. Juli 2026, 18:36 UTC

News

Social Media

Krystal Biotech Inc shares are lower today amid trading volatility, despite a planned inclusion in the S&P MidCap 400 on July 24.

20. Juli 2026, 21:21 UTC

News

Krystal Biotech Inc. will replace Taylor Morrison in the S&P MidCap 400 on July 24, 2026. The stock is lower in after-hours trading.

Peer-Vergleich

Kursveränderung

Krystal Biotech Inc Prognose

Kursziel

By TipRanks

24.95% Vorteil

12-Monats-Prognose

Durchschnitt 403.2 USD 24.95%

Hoch 474 USD

Tief 361 USD

Basierend auf 6 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Krystal Biotech Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

6 ratings

Buy

Halten

Sell

Basierend auf 6 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Krystal Biotech Inc – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Krystal Biotech Inc

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.